Brian G. Lawhorn, Ph.D. - Publications

2004 Cornell University, Ithaca, NY, United States 
Barton Professor of Chemistry

9/22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Lawhorn BG, Philp J, Zhao Y, Louer C, Hammond M, Cheung M, Fries H, Graves AP, Shewchuk L, Wang L, Cottom JE, Qi H, Zhao H, Totoritis R, Zhang G, et al. Identification of Purines and 7-Deazapurines as Potent and Selective Type I Inhibitors of Troponin I-Interacting Kinase (TNNI3K). Journal of Medicinal Chemistry. 58: 7431-48. PMID 26355916 DOI: 10.1021/acs.jmedchem.5b00931  0.92
2013 Vagnozzi RJ, Gatto GJ, Kallander LS, Hoffman NE, Mallilankaraman K, Ballard VL, Lawhorn BG, Stoy P, Philp J, Graves AP, Naito Y, Lepore JJ, Gao E, Madesh M, Force T. Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart. Science Translational Medicine. 5: 207ra141. PMID 24132636 DOI: 10.1126/scitranslmed.3006479  0.92
2009 Swingle MR, Amable L, Lawhorn BG, Buck SB, Burke CP, Ratti P, Fischer KL, Boger DL, Honkanen RE. Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and( beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors. The Journal of Pharmacology and Experimental Therapeutics. 331: 45-53. PMID 19592665 DOI: 10.1124/jpet.109.155630  0.92
2006 Lawhorn BG, Boga SB, Wolkenberg SE, Colby DA, Gauss CM, Swingle MR, Amable L, Honkanen RE, Boger DL. Total synthesis and evaluation of cytostatin, its C10-C11 diastereomers, and additional key analogues: impact on PP2A inhibition. Journal of the American Chemical Society. 128: 16720-32. PMID 17177422 DOI: 10.1021/ja066477d  0.92
2006 Lawhorn BG, Boga SB, Wolkenberg SE, Boger DL. Total synthesis of cytostatin Heterocycles. 70: 65-70.  0.92
2004 Lawhorn BG, Mehl RA, Begley TP. Biosynthesis of the thiamin pyrimidine: the reconstitution of a remarkable rearrangement reaction. Organic & Biomolecular Chemistry. 2: 2538-46. PMID 15326535 DOI: 10.1039/B405429F  0.92
2004 Lawhorn BG, Gerdes SY, Begley TP. A genetic screen for the identification of thiamin metabolic genes. The Journal of Biological Chemistry. 279: 43555-9. PMID 15292217 DOI: 10.1074/jbc.M404284200  0.92
2003 Ge Y, Lawhorn BG, ElNaggar M, Sze SK, Begley TP, McLafferty FW. Detection of four oxidation sites in viral prolyl-4-hydroxylase by top-down mass spectrometry. Protein Science : a Publication of the Protein Society. 12: 2320-6. PMID 14500890 DOI: 10.1110/ps.03244403  0.92
2002 Ge Y, Lawhorn BG, ElNaggar M, Strauss E, Park JH, Begley TP, McLafferty FW. Top down characterization of larger proteins (45 kDa) by electron capture dissociation mass spectrometry. Journal of the American Chemical Society. 124: 672-8. PMID 11804498 DOI: 10.1021/ja011335z  0.92
Low-probability matches
2021 Glogowski MP, Matthews JM, Lawhorn BG, Minbiole KPC. Diastereoselective Copper-Mediated Conjugate Addition of Functionalized Magnesiates for the Preparation of Bisaryl Nrf2 Activators. The Journal of Organic Chemistry. PMID 33555189 DOI: 10.1021/acs.joc.0c02639  0.01
2020 Patterson JR, Terrell LR, Donatelli CA, Holt DA, Jolivette LJ, Rivero RA, Roethke TJ, Shu A, Stoy P, Ye G, Youngman M, Lawhorn BG. Design and Optimization of an Acyclic Amine Series of TRPV4 Antagonists by Electronic Modulation of Hydrogen Bond Interactions. Journal of Medicinal Chemistry. PMID 33201708 DOI: 10.1021/acs.jmedchem.0c01303  0.01
2020 Lawhorn BG, Brnardic EJ, Behm DJ. Recent advances in TRPV4 agonists and antagonists. Bioorganic & Medicinal Chemistry Letters. 127022. PMID 32063431 DOI: 10.1016/j.bmcl.2020.127022  0.01
2019 Brooks CA, Barton LS, Behm DJ, Brnardic E, Costell M, Holt DA, Jolivette LJ, Matthews JM, McAtee JJ, McCleland BW, Patterson JR, Pero JE, Rivero RA, Roethke TJ, Sanchez RM, ... ... Lawhorn BG, et al. Discovery of GSK3527497: A candidate for the inhibition of Transient Receptor Potential Vanilloid-4 (TRPV4). Journal of Medicinal Chemistry. PMID 31532662 DOI: 10.1021/acs.jmedchem.9b01247  0.01
2019 Brooks CA, Barton LS, Behm DJ, Eidam HS, Fox RM, Hammond M, Hoang TH, Holt DA, Hilfiker MA, Lawhorn BG, Patterson JR, Stoy P, Roethke TJ, Ye G, Zhao S, et al. Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4). Acs Medicinal Chemistry Letters. 10: 1228-1233. PMID 31413810 DOI: 10.1021/acsmedchemlett.9b00274  0.01
2018 Pero JE, Matthews J, Behm DJ, Brnardic E, Brooks CA, Budzik BW, Costell M, Donatelli C, Eisennagel S, Erhard KF, Fischer M, Holt DA, Jolivette L, Li H, Li P, ... ... Lawhorn BG, et al. Design and Optimization of Sulfone Pyrrolidine Sulfonamide Antagonists of Transient Receptor Potential Vanilloid-4 (TRPV4) with In Vivo Activity in a Pulmonary Edema Model. Journal of Medicinal Chemistry. PMID 30500190 DOI: 10.1021/acs.jmedchem.8b01344  0.01
2018 Brnardic EJ, Ye G, Brooks C, Donatelli C, Barton L, McAtee J, Sanchez RM, Shu A, Erhard K, Terrell L, Graczyk-Millbrandt G, He Y, Costell MH, Behm DJ, Roethke T, ... ... Lawhorn BG, et al. Discovery of Pyrrolidine Sulfonamides as Selective and Orally Bioavailable Antagonists of Transient Receptor Potential Vanilloid-4 (TRPV4). Journal of Medicinal Chemistry. PMID 30335378 DOI: 10.1021/acs.jmedchem.8b01317  0.01
2018 Kallander LS, Washburn D, Hilfiker MA, Eidam HS, Lawhorn BG, Prendergast J, Fox R, Dowdell S, Manns S, Hoang T, Zhao S, Ye G, Hammond M, Holt DA, Roethke T, et al. Reverse Hydroxamate Inhibitors of Bone Morphogenetic Protein 1. Acs Medicinal Chemistry Letters. 9: 736-740. PMID 30034610 DOI: 10.1021/acsmedchemlett.8b00173  0.01
2018 Philp J, Lawhorn BG, Graves AP, Shewchuk L, Rivera KL, Jolivette LJ, Holt DA, Gatto GJ, Kallander LS. 4,6-Diaminopyrimidines as Highly Preferred Troponin I-Interacting Kinase (TNNI3K) Inhibitors. Journal of Medicinal Chemistry. PMID 29561151 DOI: 10.1021/acs.jmedchem.8b00125  0.01
2017 Lawhorn BG, Tran T, Hong VS, Morgan LA, Le BT, Harpel MR, Jolivette L, Diaz E, Schwartz B, Gross JW, Tomaszek T, Semus S, Concha N, Smallwood A, Holt DA, et al. Discovery of renin inhibitors containing a simple aspartate binding moiety that imparts reduced P450 inhibition. Bioorganic & Medicinal Chemistry Letters. PMID 28985999 DOI: 10.1016/j.bmcl.2017.09.046  0.01
2016 Lawhorn BG, Philp J, Graves AP, Holt DA, Gatto GJ, Kallander LS. Substituent Effects on Drug-Receptor H-bond Interactions: Correlations Useful for the Design of Kinase Inhibitors. Journal of Medicinal Chemistry. 59: 10629-10641. PMID 27933961 DOI: 10.1021/acs.jmedchem.6b01342  0.01
2016 Lawhorn BG, Philp J, Graves AP, Shewchuk L, Holt DA, Gatto GJ, Kallander LS. GSK114: A selective inhibitor for elucidating the biological role of TNNI3K. Bioorganic & Medicinal Chemistry Letters. PMID 27246618 DOI: 10.1016/j.bmcl.2016.05.033  0.01
2007 Boger D, Lawhorn B, Boga S, Wolkenberg S, Colby D, Gauss C, Swingle M, Amable L, Honkanen R. Synthesis of Cytostatin Synfacts. 2007: 0456-0456. DOI: 10.1055/s-2007-968390  0.01
Hide low-probability matches.